Plasma melatonin and the hormone-dependency of human breast cancer

D. N. Danforth, L. Tamarkin, J. J. Mulvihill, C. S. Bagley, Marc E Lippman

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

We studied the 24-hour plasma melatonin profile in three groups of women: normal individuals, women with breast cancer, and women atf high risk for breast cancer, to determine the relationship of plasma melatonin to this malignancy. The mean daytime (nadir) and mean nighttime (peak) plasma levels for the normal subjects were 9.1 pg/mL and 70.9 pg/mL, respectively. The mean daytime and nighttime plasma levels, and the range of melatonin day to night differences for women with breast cancer and women at high risk for breast cancer were comparable to each other and to the normal subjects, with no statistically significant differences noted. The patients with breast cancer demonstrated a striking correlation between the melatonin diurnal rhythm and the steroid receptor content of the primary tumor. Women with estrogen (ER) or progesterone (PR) receptor-positive tumors had a significantly lower mean plasma melatonin day to night difference than did patients with ER- or PR-negative tumors. Further, a strong inverse correlation was observed between the plasma melatonin concentration and the quantities of ER and PR in the primary tumor; the lower the plasma melatonin concentration the greater the amount of either receptor in the primary tumor. Plasma melatonin did not correlate with tumor glucocorticoid receptor content or stage of breast cancer among these patients, or with menopausal status, age, parity, or the plasma levels of estrone, estradiol, progesterone, follicle-stimulating hormone (FSH), or luteinizing hormone (LH) among all individuals studied. Plasma melatonin was also independent of the degree of risk for breast cancer among the high-risk patients. These findings suggest an important relationship between the plasma melatonin diurnal rhythm and the hormone dependency of human breast cancer, and may have implications for both the prognosis and treatment of this malignancy.

Original languageEnglish
Pages (from-to)941-948
Number of pages8
JournalJournal of Clinical Oncology
Volume3
Issue number7
StatePublished - Sep 25 1985
Externally publishedYes

Fingerprint

Melatonin
Hormones
Breast Neoplasms
Neoplasms
Progesterone
Circadian Rhythm
Estrogens
Estrone
Steroid Receptors
Glucocorticoid Receptors
Follicle Stimulating Hormone
Progesterone Receptors
Luteinizing Hormone
Parity
Estrogen Receptors
Estradiol

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Danforth, D. N., Tamarkin, L., Mulvihill, J. J., Bagley, C. S., & Lippman, M. E. (1985). Plasma melatonin and the hormone-dependency of human breast cancer. Journal of Clinical Oncology, 3(7), 941-948.

Plasma melatonin and the hormone-dependency of human breast cancer. / Danforth, D. N.; Tamarkin, L.; Mulvihill, J. J.; Bagley, C. S.; Lippman, Marc E.

In: Journal of Clinical Oncology, Vol. 3, No. 7, 25.09.1985, p. 941-948.

Research output: Contribution to journalArticle

Danforth, DN, Tamarkin, L, Mulvihill, JJ, Bagley, CS & Lippman, ME 1985, 'Plasma melatonin and the hormone-dependency of human breast cancer', Journal of Clinical Oncology, vol. 3, no. 7, pp. 941-948.
Danforth DN, Tamarkin L, Mulvihill JJ, Bagley CS, Lippman ME. Plasma melatonin and the hormone-dependency of human breast cancer. Journal of Clinical Oncology. 1985 Sep 25;3(7):941-948.
Danforth, D. N. ; Tamarkin, L. ; Mulvihill, J. J. ; Bagley, C. S. ; Lippman, Marc E. / Plasma melatonin and the hormone-dependency of human breast cancer. In: Journal of Clinical Oncology. 1985 ; Vol. 3, No. 7. pp. 941-948.
@article{82833d44aeb64ed59e095376fe420caf,
title = "Plasma melatonin and the hormone-dependency of human breast cancer",
abstract = "We studied the 24-hour plasma melatonin profile in three groups of women: normal individuals, women with breast cancer, and women atf high risk for breast cancer, to determine the relationship of plasma melatonin to this malignancy. The mean daytime (nadir) and mean nighttime (peak) plasma levels for the normal subjects were 9.1 pg/mL and 70.9 pg/mL, respectively. The mean daytime and nighttime plasma levels, and the range of melatonin day to night differences for women with breast cancer and women at high risk for breast cancer were comparable to each other and to the normal subjects, with no statistically significant differences noted. The patients with breast cancer demonstrated a striking correlation between the melatonin diurnal rhythm and the steroid receptor content of the primary tumor. Women with estrogen (ER) or progesterone (PR) receptor-positive tumors had a significantly lower mean plasma melatonin day to night difference than did patients with ER- or PR-negative tumors. Further, a strong inverse correlation was observed between the plasma melatonin concentration and the quantities of ER and PR in the primary tumor; the lower the plasma melatonin concentration the greater the amount of either receptor in the primary tumor. Plasma melatonin did not correlate with tumor glucocorticoid receptor content or stage of breast cancer among these patients, or with menopausal status, age, parity, or the plasma levels of estrone, estradiol, progesterone, follicle-stimulating hormone (FSH), or luteinizing hormone (LH) among all individuals studied. Plasma melatonin was also independent of the degree of risk for breast cancer among the high-risk patients. These findings suggest an important relationship between the plasma melatonin diurnal rhythm and the hormone dependency of human breast cancer, and may have implications for both the prognosis and treatment of this malignancy.",
author = "Danforth, {D. N.} and L. Tamarkin and Mulvihill, {J. J.} and Bagley, {C. S.} and Lippman, {Marc E}",
year = "1985",
month = "9",
day = "25",
language = "English",
volume = "3",
pages = "941--948",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Plasma melatonin and the hormone-dependency of human breast cancer

AU - Danforth, D. N.

AU - Tamarkin, L.

AU - Mulvihill, J. J.

AU - Bagley, C. S.

AU - Lippman, Marc E

PY - 1985/9/25

Y1 - 1985/9/25

N2 - We studied the 24-hour plasma melatonin profile in three groups of women: normal individuals, women with breast cancer, and women atf high risk for breast cancer, to determine the relationship of plasma melatonin to this malignancy. The mean daytime (nadir) and mean nighttime (peak) plasma levels for the normal subjects were 9.1 pg/mL and 70.9 pg/mL, respectively. The mean daytime and nighttime plasma levels, and the range of melatonin day to night differences for women with breast cancer and women at high risk for breast cancer were comparable to each other and to the normal subjects, with no statistically significant differences noted. The patients with breast cancer demonstrated a striking correlation between the melatonin diurnal rhythm and the steroid receptor content of the primary tumor. Women with estrogen (ER) or progesterone (PR) receptor-positive tumors had a significantly lower mean plasma melatonin day to night difference than did patients with ER- or PR-negative tumors. Further, a strong inverse correlation was observed between the plasma melatonin concentration and the quantities of ER and PR in the primary tumor; the lower the plasma melatonin concentration the greater the amount of either receptor in the primary tumor. Plasma melatonin did not correlate with tumor glucocorticoid receptor content or stage of breast cancer among these patients, or with menopausal status, age, parity, or the plasma levels of estrone, estradiol, progesterone, follicle-stimulating hormone (FSH), or luteinizing hormone (LH) among all individuals studied. Plasma melatonin was also independent of the degree of risk for breast cancer among the high-risk patients. These findings suggest an important relationship between the plasma melatonin diurnal rhythm and the hormone dependency of human breast cancer, and may have implications for both the prognosis and treatment of this malignancy.

AB - We studied the 24-hour plasma melatonin profile in three groups of women: normal individuals, women with breast cancer, and women atf high risk for breast cancer, to determine the relationship of plasma melatonin to this malignancy. The mean daytime (nadir) and mean nighttime (peak) plasma levels for the normal subjects were 9.1 pg/mL and 70.9 pg/mL, respectively. The mean daytime and nighttime plasma levels, and the range of melatonin day to night differences for women with breast cancer and women at high risk for breast cancer were comparable to each other and to the normal subjects, with no statistically significant differences noted. The patients with breast cancer demonstrated a striking correlation between the melatonin diurnal rhythm and the steroid receptor content of the primary tumor. Women with estrogen (ER) or progesterone (PR) receptor-positive tumors had a significantly lower mean plasma melatonin day to night difference than did patients with ER- or PR-negative tumors. Further, a strong inverse correlation was observed between the plasma melatonin concentration and the quantities of ER and PR in the primary tumor; the lower the plasma melatonin concentration the greater the amount of either receptor in the primary tumor. Plasma melatonin did not correlate with tumor glucocorticoid receptor content or stage of breast cancer among these patients, or with menopausal status, age, parity, or the plasma levels of estrone, estradiol, progesterone, follicle-stimulating hormone (FSH), or luteinizing hormone (LH) among all individuals studied. Plasma melatonin was also independent of the degree of risk for breast cancer among the high-risk patients. These findings suggest an important relationship between the plasma melatonin diurnal rhythm and the hormone dependency of human breast cancer, and may have implications for both the prognosis and treatment of this malignancy.

UR - http://www.scopus.com/inward/record.url?scp=0021866459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021866459&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 941

EP - 948

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -